Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 10 includes Advanced Micro Devices, Novo Nordisk ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

(Reuters) -Eli Lilly on Thursday suggested ... about signs of weakness in sales of the drugs. Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

INDIANAPOLIS — Eli Lilly’s profit ... Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment ...